M
Madhu K. Natarajan
Researcher at Population Health Research Institute
Publications - 182
Citations - 10797
Madhu K. Natarajan is an academic researcher from Population Health Research Institute. The author has contributed to research in topics: Percutaneous coronary intervention & Myocardial infarction. The author has an hindex of 37, co-authored 168 publications receiving 9945 citations. Previous affiliations of Madhu K. Natarajan include McMaster University & University of Toronto.
Papers
More filters
Journal ArticleDOI
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
Shamir R. Mehta,Salim Yusuf,Ron J.G. Peters,Michel E. Bertrand,Basil S. Lewis,Madhu K. Natarajan,Klas Malmberg,Hans-Jürgen Rupprecht,Feng Zhao,Susan Chrolavicius,Ingrid Copland,Keith A.A. Fox +11 more
TL;DR: In patients with acute coronary syndrome receiving aspirin, a strategy of clopidogrel pretreatment followed by long-term therapy is beneficial in reducing major cardiovascular events, compared with placebo.
Journal ArticleDOI
Transcatheter Aortic Valve Implantation for the Treatment of Severe Symptomatic Aortic Stenosis in Patients at Very High or Prohibitive Surgical Risk: Acute and Late Outcomes of the Multicenter Canadian Experience
Josep Rodés-Cabau,John G. Webb,Anson Cheung,Jian Ye,Eric Dumont,Christopher M. Feindel,Mark Osten,Madhu K. Natarajan,James L. Velianou,Giuseppe Martucci,Benoit DeVarennes,Robert J. Chisholm,Mark D. Peterson,Samuel V. Lichtenstein,Fabian Nietlispach,Daniel Doyle,Robert DeLarochellière,Kevin Teoh,Victor Chu,Adrian Dancea,Kevin Lachapelle,Asim N. Cheema,David A. Latter,Eric Horlick +23 more
TL;DR: A TAVI program including both TF and TA approaches was associated with comparable mortality as predicted by surgical risk calculators for the treatment of patients at very high or prohibitive surgical risk, including porcelain aorta and frail patients.
Journal ArticleDOI
Early versus Delayed Invasive Intervention in Acute Coronary Syndromes
Shamir R. Mehta,Christopher B. Granger,William E. Boden,Philippe Gabriel Steg,Jean-Pierre Bassand,David P. Faxon,Rizwan Afzal,Susan Chrolavicius,Sanjit S. Jolly,Petr Widimsky,Alvaro Avezum,Hans-Jürgen Rupprecht,Jun Zhu,Jacques Col,Madhu K. Natarajan,Craig Horsman,Keith A.A. Fox,Salim Yusuf +17 more
TL;DR: Early intervention did not differ greatly from delayed intervention in preventing the primary outcome, but it did reduce the rate of the composite secondary outcome of death, myocardial infarction, or refractory ischemia and was superior to delayed Intervention in high-risk patients.
Journal ArticleDOI
PexeLizumab for Acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial
Paul W. Armstrong,N. Bett,David Brieger,D. Chew,R. Dick,A. Farshid,P Garrahy,B. Gunalingham,R. Hendriks,John D. Horowitz,Nigel Jepson,Jeffrey Lefkovits,S. Lo,Ian T. Meredith,G. Nelson,G. New,Ananth M. Prasan,J. Rankin,P. Thompson,S. Worthley,R. Yadav,Kurt Huber,Gerald Maurer,P. Siostrzonek,J. Boland,C. Covens,Walter Desmet,K. Dujardin,M. Vrolix,Christopher E. Buller,P. Klinke,C. Lazzam,Sohrab Lutchmedial,Mina Madan,Madhu K. Natarajan,François Reeves,J. Rodes Cabau,Barry Rose,Erick Schampaert,Pierre Theroux,Mouhieddin Traboulsi,John G. Webb,Robert C. Welsh,R. Zimmerman,M. Aschermann,M. Branny,T. Budesinsky,P. Cervinka,H. Frantisek,T. Frantisek,L. Groch,P. Kala,M. Ritcher,R. Rokyta,J. St'asek,R. Stipal,I. Varvarovsky,D. Zamanek,M. Zelizko,T. Toftegaard Nielsen,K. Rasmussen,P. RiisHansen,P. Thayssen,P. Beaufils,P. Geslin,Y. Gottwalles,H. Lebreton,H. LeMarec,Gilles Montalescot,G. Roul,Phillippe Gabriel Steg,C. Tronc,H. J. Berger,Martin Borggrefe,J. Brachmann,P. Braun,M. Buerke,H. R. Figulla,H. Guelker,G. Hasenfuss,T. Heitzer,Hubertus Heuer,E. Hoffman,S. Hoffmann,K. H. Kuck,Franz-Josef Neumann,J. Neuzner,M. Rau,G. Richardt,Heribert Schunkert,R. Stern,W. Von Schedit,P. C. Werner,R. Zahn,G. Binetti,E. Bramucci,G. Carosio,A. Manari,A. Marzocchi,M. Medda,G. Piovaccari,Alessandro Politi,L. Vignali,R. Violini,M. Zanchetta,R. Zanini,K. Marques,H. Otto Peels,T. Slagboom,P. C. Smits,Harry Suryapranata,M. J. Suttorp,M. Van-DerEnt,I. Crozier,G. Devlin,Sian E. Harding,Harvey D. White,G. Wilkins,M. Krzeminska-Pakula,K. Loboz-Grudzien,W. Ruźyllo,W. Tracz,M. Trusz-Gluza,M. Almeida,J. Correiada Cunha,P. Farto Abreu,L. Mourão,H. Pereira,L. Providencia,R. Vascoda Gama,A. Bertriu,C. Cuellas,E. Esplugas,E. Garcia Fernandez,X. Goicolea,J. M. Hernandez,C. Macaya,V. Mainar,Angel Martínez Sánchez,P. Erikksson,Stefan James,G. Olivercrona,C. M. Pripp,E. Camenzind,M Pfisterer,M. Pieper,Hans Rickli,R. Acheatel,A. Ahmad,A. Albirini,R. Allen,A. Amkieh,H. V. Anderson,J. Anderson,B. Armstrong,W. Asfour,T. Ayres,M. Azrin,Z. Baber,L. Barr,G. Barsness,J. Batty,Mahesh Bikkina,James C. Blankenship,Duncan J. Campbell,P. Caples,T. Carlson,John C. Chambers,H. Chandna,B. Cheek,J. Cheirif,A. Chu,H. Colfer,B. Crenshaw,S. David,A. DeFranco,J. Dehoya,J. Diez,G. Eaton,E. Eichhorn,M. El Shahawy,T. Farah,W. Felten,D. Fortuin,Malcolm T. Foster,D. S. Gantt,J. Gard,M. Ghali,R. Glaser,M. Greenberg,John H. Griffin,G. Hanovich,N. Hassinger,S. Heifetz,Timothy D. Henry,J. Hermiller,J. Hernandez,R. Hodson,M. Imburgia,B. Iteld,Z. Jafar,A. Jain,N. Jamal,G. Kang,Ronald P. Karlsberg,S. Khanal,S. Khoury,J. Kieval,Robert Kipperman,Robert Kipperman,B. Kluck,David F. Kong,E. Kosinski,M. Kozak,H. Kozman,P. Kraft,A. Labroo,P. Lai,N. Lakkis,G. Lane,B. Laretta,D. Lee,M. Leesar,J. Leggett,M. Levine,S. Lieberman,M. Lim,J. Luber,V. Marques,K. Marzo,J. McGarvey,G. McKendall,B. McLellan,M. Meengs,D. Mego,A. Mehra,J. A. Messenger,J. O. Messenger,M. Midei,Matthew R. Miller,David J. Moliterno,K. Momah,M. Mowdy,A. Nahhas,J. Navas,A. Niederman,T. Nygaard,William W. O'Neill,Kunal Patel,S. Pfau,V. Pompili,D. Purdy,B. Reddy,Alan Rees,J. Reiner,A. Riba,E. Rivera,David T. Roberts,A. Rosenblatt,W. Rowe,S. Rowley,D. Rubin,K. Saeian,Frank S. Saltiel,S. Sample,B. Sanchez,I. Sarembock,Jorge F. Saucedo,T. Schreiber,Ranjit Shah,M. Singh,J. Slater,R. Small,C. Staniloae,P. S. Sundram,L. Swenson,G. Symkoviak,K. Tam,A. Taussig,J. Thatcher,P. Tolerico,J. Trippi,S. Turk,K. Van Osdol,R. Vicari,A. Virmani,M. Warner,R. Webel,J. Wertheimer,G. Williams,Jonathan H. Williams,M. Winniford,D. Wohns,D. X.M. Zhao +293 more
TL;DR: In this large clinical trial of patients treated with primary PCI for STEMI, mortality was low and unaffected by administration of pexelizumab, and the composite end points of death, shock, or heart failure were similar.
Journal ArticleDOI
Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction
Shamir R. Mehta,John W. Eikelboom,Madhu K. Natarajan,Rafael Diaz,Cheelong Yi,Raymond J. Gibbons,Salim Yusuf +6 more
TL;DR: Patients with inferior MI who also have RV myocardial involvement are at increased risk of death, shock and arrhythmias, and this increased risk is related to the presence of RV myCardial involvement itself rather than the extent of LV myocardia damage.